Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Tardive dyskinesia Stories

2012-07-30 23:00:17

According to court documents, on May 29th, 2012, a Minnesota woman, Marilyn Abicht, filed a lawsuit in Minnesota District Court (case no. 0:2012cv01278) alleging that Reglan (metoclopramide) caused her tardive dyskinesia. Reglan (metoclopramide) is a drug used to help with the digestive process and reduce the symptoms of acid reflux and heartburn. It has been in the market since 1996. In 2009, the US FDA issued a black box warning that treatment with metoclopramide (Reglan) can cause tardive...

2012-07-25 10:23:25

SAN DIEGO, July 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2012 financial results after the Nasdaq market closes on Tuesday, July 31, 2012. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, July 31, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by...

2012-06-21 10:26:00

Consumers have no day in court simply because they took generics WASHINGTON, June 21, 2012 /PRNewswire-USNewswire/ -- Carrie Scott went in to the hospital for abnormal bleeding. Days later she returned home without her hand and forearm. The generic form of Phenergan was given improperly, apparently from an inadequate warning label. Scott has no legal recourse because a generic drug caused her injury, rather than its brand-name equivalent. Saturday marks the one-year anniversary of...

2012-05-29 06:24:55

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2012 Global Healthcare Conference in New York. The live presentation takes place on Tuesday, June 5 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. If you are...

2012-05-04 10:25:26

SAN DIEGO, May 4, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 37th Annual Health Care Conference in Boston. The live presentation takes place on Wednesday, May 9 at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. If you...

2012-05-01 10:25:50

- Investigator 'hopeful that the Unified Dyskinesia Rating Scale will be a useful tool to help translate research into treatments' - NEW YORK, May 1, 2012 /PRNewswire-USNewswire/ -- Researchers funded by The Michael J. Fox Foundation (MJFF) have identified the best measure for testing patient response to therapies to treat dyskinesia, the debilitating, uncontrollable movements that are often a side effect of Parkinson's disease (PD) drugs. MJFF has made dyskinesia a top research priority...

2012-04-25 10:25:36

SAN DIEGO, April 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2012 financial results after the Nasdaq market closes on Wednesday, May 2, 2012. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, May 2, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live...

2012-03-27 10:23:59

SAN DIEGO, March 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 11(th) Annual Needham Healthcare Conference in New York. The live presentation takes place on Tuesday, April 3 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com....

2012-03-26 10:23:49

SAN DIEGO, March 26, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, data from one site was removed due to the inconsistent and incorrect application of the efficacy assessment protocol. With this site removed, the results showed a significant reduction in tardive dyskinesia symptoms at end of two weeks of active treatment with 50mg...